Reactogenicity after rAd5 boost by study group.

NIAID Data Ecosystem2026-03-07 收录

疫苗反应原性

临床试验安全性

数据链接：

https://figshare.com/articles/dataset/_Reactogenicity_after_rAd5_boost_by_study_group_/407651 数据链接链接失效反馈

官方服务：

资源简介：

Reactogenicity after rAd5 boost by study group.

创建时间：

2011-09-12

Local Reactions.

疫苗不良反应监测

临床试验安全性

†3×2 cm abscess beginning three days after second immunization; subject withdrawn from further doses of vaccine; abscess resolved spontaneously. ††Subject developed severe pain, swelling and erythema,

NIAID Data Ecosystem90

CsA-specific and general side effects during the Medication and “ Placebo ” condition.

药物副作用评估

临床试验安全性

Treatment groups did not significantly differ in reported CsA-specific and general side effects analyzed with the GASE, neither before study participation (GASE Baseline), nor during the Medication an

NIAID Data Ecosystem40

All treatment-related adverse events (probable or possible), listed by system organ class (n = 21 in the G-CSF, n = 20 in the placebo group).

药物不良反应监测

临床试验安全性

All treatment-related adverse events (probable or possible), listed by system organ class (n = 21 in the G-CSF, n = 20 in the placebo group).

NIAID Data Ecosystem30

Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.

临床试验安全性

肾功能分层

Summary of Number of participants experiencing grade 3–4 AEs, SAEs or death by treatment and baseline CLcr (mL/min) groups through 96 weeks.

NIAID Data Ecosystem60

Adverse events * and un-wanted side effects † reported in included studies.